Postmarketing Cases of Enfortumab Vedotin –Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis

This case series study uses data from the FDA Adverse Event Reporting System to investigate a potential association between enfortumab vedotin treatment and Stevens-Johnson Syndrome and toxic epidermal necrolysis.

Source: JAMA Dermatology - September 8, 2021 Category: Dermatology Source Type: research